Myra Vision Announces Funding to Advance Calibreye Surgical Treatment for Glaucoma Patients

Myra Vision, which is a Shifamed portfolio company, announced the closing of its $25 million Series B financing to further product development, scale manufacturing capabilities, and support first-in-human investigation of the company's Calibreye System, a novel treatment that aims to optimize reduction of IOP for patients with moderate to advanced glaucoma.

"The Calibreye System is designed to allow physicians to safely optimize aqueous outflow and effectively manage the evolving clinical needs of each patient," Robert Chang, President and Chief Executive Officer of Myra Vision, said in a company news release. "We are pleased to close this round of financing with strong continued support from our investors. The team has made tremendous progress and we look forward to the next step towards delivering this meaningful solution for glaucoma patients."

The financing was led by Cormorant Asset Management, with significant participation from The Capital Partnership (TCP), the PA MedTech VC Fund and Shifamed angel investors.